http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
공동주택 사전성능평가를 위한 성능평가 시스템 개발에 관한 연구
강미선,이상현,김하나,엄혜진 대한건축학회 2003 대한건축학회논문집 Vol.19 No.10
The purpose of this study is to propose an evaluation framework for Collective Housing and to develop the Design Evaluation System. The Performance Evaluation System of Collective Housing in the Design Development Stage evaluates its design results by running CAD program. The results are automatically reflected in the design process. The scope of this study will be limited to the contents within the Barrier Free Design. Running the design evaluation program requires the conversion of design forms and design checklist to computerized ones. To efficiently conduct this process, First, organize the existing guideline of the Barrier Free Design. Second, define attributes of each part in Building Data Model with the analysis of the checklist. Third, develop the Performance Analysis agent that compares Building Data Model with translated checklists. Finally, verify the efficiency of the Performance Evaluation System by seeking experts' advice on the result of the program.
염색체 위치 특이적 삽입과 안정적인 유전자 발현을 유도하는 플라스미드 백터의 제작
문영준,강윤성,최지혜,손진숙,민나영,이광호 中央大學校 基礎科學硏究所 2002 基礎科學硏究所 論文集 Vol.16 No.-
Insertion of reporter constructs into the mammalian genome leads to variable gene expression due to position effects at the site of integration. This random integration has limited the gene therapy of human genetic disorders by its undesirable effects. We report here the newly constructed plasmid vector(pIRES-neo-YJ) based on the concepts of homologous recombination and position-independent promoter enhancing of beta-globin matrix attachment region(Glb-MAR). chromosome 7 centromere-specific alpha satellite(alphoid) DNA sequence was cloned into pIRES-neo-YJ for homologous recombination of the cloned gene with the centromeric region of chromosome 7, which is genetically silent. Beta Glb-MAR sequence that allows high levels of transcription independent of the chromosomal site of integration was also inserted into pIRES-neo-YJ to ensure the stable and higher expression of the cloned genes. We expect that pIRES-neo-YJ would provide a valuable tool to eliminate random integration of cloned genes into the undesirable chromosomal region and their short-lived expression which often encounters during the construction of transgenic animals and human gene therapy.
Hye Yoon Choi,Gwang-Hoon Lee,Na-Hye Park,Hye Eun Jo,Tae Ku Kang,Woori Jo,Kil-Soo Kim 한국실험동물학회 2021 한국실험동물학회 학술발표대회 논문집 Vol.2021 No.7
Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF) consists of four research facilities (new drug development center, medical device development center, laboratory animal center, and clinical drug manufacturing center). The laboratory animal center is a facility to support the development of new drugs and medical devices, and plays a key role in evaluating the efficacy and safety tests of new drugs and medical devices through the management of laboratory animals, production of animal disease model, biometric analysis, experimental animal resource management, and in-vivo tests. The laboratory animal center is advancing image analysis equipment and surgical techniques to support high-quality animal experiments requiring high technology, and is improving the welfare of experimental animals through professional animal management, health monitoring, IACUC approval, post approval monitoring, and veterinary care to achieve reliable research results. DGMIF LAC has facilities for rodents including mouse and rats, rabbits, dogs, pigs, and monkeys, and the rodent animal facility is using IVC and ISO-N cage system and areas are divided into four areas including species conservation area, small animal testing area, re-entry area for imaging analysis, and ABSL-2 area for infection tests using ABSL-2 level microorganism. For high-quality animal management, DGMIF LAC acquired ICLAS PEP (Performance evaluation program for diagnostic laboratories, International Council for Laboratory Animal Science) accredited for the first in South Korea in 2017, KESAF (Korean Excellent Laboratory Animal Facility) in 2016, and AAALAC (The Association for Assessment and Accreditation of Laboratory Animal Care) International Full Accreditation in 2020. It is the only institution in Daegu and North Gyeongsang Province that that has received these two accreditations. Since the operation of the animal facility in 2014, the number of laboratory animals has been steadily increasing. Furthermore, additional facility for mini-pigs was completely built. DGMIF LAC will play a major role in the evaluation of the effecacy tests for new drugs and medical devices through the maintenance and development of high-quality laboratory animals that comply with international standards.
Na, Keun,Shin, Heon,Cho, Jin-Young,Jung, Sang Hee,Lim, Jaeseung,Lim, Jong-Sun,Kim, Eun Ah,Kim, Hye Sun,Kang, Ah Reum,Kim, Ji Hye,Shin, Jeong Min,Jeong, Seul-Ki,Kim, Chae-Yeon,Park, Jun Young,Chung, Hy American Chemical Society 2017 JOURNAL OF PROTEOME RESEARCH Vol.16 No.12
<P>One of the major goals of the Chromosome-Centric Human Proteome Project (C-HPP) is to fill the knowledge gaps between human genomic information and the corresponding proteomic information. These gaps are due to “missing” proteins (MPs)predicted proteins with insufficient evidence from mass spectrometry (MS), biochemical, structural, or antibody analysesthat currently account for 2579 of the 19587 predicted human proteins (neXtProt, 2017-01). We address some of the lessons learned from the inconsistent annotations of missing proteins in databases (DB) and demonstrate a systematic proteogenomic approach designed to explore a potential new function of a known protein. To illustrate a cautious and strategic approach for characterization of novel function in vitro and in vivo, we present the case of Na(+)/H(+) exchange regulatory cofactor 1 (NHERF1/SLC9A3R1, located at chromosome 17q25.1; hereafter NHERF1), which was mistakenly labeled as an MP in one DB (Global Proteome Machine Database; GPMDB, 2011-09 release) but was well known in another public DB and in the literature. As a first step, NHERF1 was determined by MS and immunoblotting for its molecular identity. We next investigated the potential new function of NHERF1 by carrying out the quantitative MS profiling of placental trophoblasts (PXD004723) and functional study of cytotrophoblast JEG-3 cells. We found that NHERF1 was associated with trophoblast differentiation and motility. To validate this newly found cellular function of NHERF1, we used the <I>Caenorhabditis elegans</I> mutant of <I>nrfl-1</I> (a nematode ortholog of <I>NHERF1</I>), which exhibits a protruding vulva (Pvl) and egg-laying-defective phenotype, and performed genetic complementation work. The <I>nrfl-1</I> mutant was almost fully rescued by the transfection of the recombinant transgenic construct that contained human <I>NHERF1</I>. These results suggest that NHERF1 could have a previously unknown function in pregnancy and in the development of human embryos. Our study outlines a stepwise experimental platform to explore new functions of ambiguously denoted candidate proteins and scrutinizes the mandated DB search for the selection of MPs to study in the future.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jprobs/2017/jprobs.2017.16.issue-12/acs.jproteome.7b00146/production/images/medium/pr-2017-00146s_0008.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/pr7b00146'>ACS Electronic Supporting Info</A></P>
Kang, Chan Woo,Jang, Kang Won,Sohn, Jinyoung,Kim, Sung-Moo,Pyo, Kyoung-Ho,Kim, Hwan,Yun, Mi Ran,Kang, Han Na,Kim, Hye Ryun,Lim, Sun Min,Moon, Yong Wha,Paik, Soonmyung,Kim, Dae Joon,Kim, Joo Hang,Cho, American Association for Cancer Research 2015 Molecular Cancer Therapeutics Vol.14 No.10
<P><I>RET</I> rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in <I>RET</I>-rearranged LADC has not been reported. The aims of the study are to explore antitumor effects and mechanisms of acquired resistance of dovitinib in <I>RET</I>-rearranged LADC. Using structural modeling and <I>in vitro</I> analysis, we demonstrated that dovitinib induced cell-cycle arrest at G<SUB>0</SUB>–G<SUB>1</SUB> phase and apoptosis by selective inhibition of RET kinase activity and ERK1/2 signaling in <I>RET</I>-rearranged LC-2/ad cells. Strong antitumor effect of dovitinib was observed in an LC-2/ad tumor xenograft model. To identify the acquired resistance mechanisms to dovitinib, LC-2/ad cells were exposed to increasing concentrations of dovitinib to generate LC-2/ad DR cells. Gene-set enrichment analysis of gene expression and phosphor-kinase revealed that Src, a central gene in focal adhesion, was activated in LC-2/ad DR cells. Saracatinib, an src kinase inhibitor, suppressed ERK1/2 phosphorylation and growth of LC-2/ad DR cells. Taken together, these findings suggest that dovitinib can be a potential therapeutic option for <I>RET</I>-rearranged LADC, in which acquired resistance to dovitinib can be overcome by targeting Src. <I>Mol Cancer Ther; 14(10); 2238–48. ©2015 AACR</I>.</P>